Breast cancer patients could be spared chemotherapy with new genetic test

Posted on: August 26, 2016

The results of research  published in the New England Journal of Medicine on 25 August suggest 2000 to 2500 Australian women could be spared chemo every year by using the MammaPrint genetic test.

The MammaPrint test is not universally accessible. Australian samples are sent to Los Angeles for testing and come with an out of pocket cost of roughly $5500 in Australia.

The medical services advisory committee is assessing an application for government funding.

Click here for more information.

Comments are closed.

WP-Backgrounds by InoPlugs Web Design and Juwelier Schönmann